返回
Island Pharmaceuticals Ltd（ILPLF）价格
ILPLF 股价走势图
ILPLF 收益
Island Pharmaceuticals Ltd
$0
0%
$0
收盘价：Jan 16, 16:00:00 GMT-5
$0
0%
$0
盘后：Jan 16, 20:00:00 GMT-5
关键数据
前收盘价
--
开盘价
--
当日区间
-
52周范围
-
交易量
--
平均成交量
--
每股收益（TTM）
--
股息收益率
--
市值
--
什么是 ILPLF？
Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-04-13. The firm is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The firm operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.